About AKLIEF® (trifarotene) Cream, 0.005%:

THE FIRST RETINOID MOLECULE FOR THE TREATMENT OF ACNE IN 20 YEARS.1

Image

AKLIEF Cream: AN INNOVATIVE APPROACH.

The first topical treatment with proven results in treating facial and truncal acne is here.1,2

THE IMPORTANCE OF RAR-γ IN ACNE.

Retinoids signal via 3 Retinoic Acid Receptor (RAR) subtypes
  • Gamma is the most prevalent RAR subtype in the skin.3
Targeting RAR-γ with retinoids has several important functions in acne via gene modification4:
  • Inflammation modulated via AP-15,6
  • Epidermal turnover and normalizing cell growth4-6

RAR=retinoic acid receptor; RAR-γ=retinoic acid receptor γ; AP-1=activator protein 1.

THE FIRST TOPICAL RETINOID MOLECULE TO SPECIFICALLY TARGET RAR-γ.1

The above is not a representation of the actual percentage of receptors in the skin. In a study of human skin biopsies, the percentage of RAR found in the skin was3: RAR-α 12-14% | RAR-β not detected | RAR-γ 87%

AKLIEF Cream:
  • Specifically targets RAR-γ, the most common retinoic acid receptor in the skin2,3
  • Potent and effective at low doses4
  • Low systemic exposure allowing use on large surface areas4
  • The exact process by which trifarotene ameliorates acne is unknown

RAR-α=retinoic acid receptor α; RAR-β=retinoic acid receptor β; RAR-γ=retinoic acid receptor γ.

A UNIQUE DELIVERY SYSTEM.

AKLIEF Vehicle contains:
  • 2 emollients
  • Cyclomethicone and medium-chain triglycerides also allow for greater spreadability9-11
  • Allantoin which is a known skin conditioning agent and protectant9,11
  • Paraben-free9
  • Simulgel® 600 PHA9
  • Non-greasy and occlusive properties
  • Allows for homogenous dispersion of active ingredients
  • Not sensitive to pH changes

Emollients are mostly lipids and oils which hydrate and improve skin softness, flexibility, and smoothness.12

 

Image

AKLIEF Cream in action THE POWER OF PRECISION.

The first topical retinoid to specifically target RAR-γ, the most prevalent receptor in the skin.2,3

WATCH NOW

PROVEN EFFICACY IN TREATING
ACNE VULGARIS IN

2,000+

PATIENTS ENROLLED IN 2 CLINICAL TRIALS2

RAPID RESULTS.* POWERFUL EFFICACY. EXCELLENT TOLERABILITY.2

View Clinical Data

*Indicating a 2-week time frame on both the face and the trunk.2

ACNE THAT'S BEYOND WHAT'S IN PLAIN SIGHT.

Patients with truncal acne may not freely talk about it with their doctors for various reasons. However, if left untreated, it can have a negative impact of their daily lives.7,8

LEARN MORE

References: 1. AKLIEF Press Release. Federal Drug Administration approval 2019. 2. Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 µg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691-1699. 3. Fisher GJ, Harvinder ST, Talwar S, et al. Immunological identification and functional quantitation of retinoic acid and retinoid X receptor proteins in human skin. J Biol Chem. 1994;269(32):20629-20635. 4. Aubert J, Piwnica D, Bertino D, et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-γ agonist trifarotene. Br J Dermatol. 2018;179(2):442-456. 5. Czernielewski L, Michel S, Bouclier M, Baker M, Hensby C. Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne. J Eur Acad Dermatol Venereol. 2001;15(suppl 3):5-12. 6. Goyette P, Chen CF, Wang W, Senguin F, Lohnes D. Characterization of retinoic acid receptor-deficient keratinocytes. J Biol Chem. 2000;275(22):16497-16505. 7. Mandy SH. Chest and back acne: A retrospective review. Adv Ther. 1995;12(6):321-332. 8. Del Rosso JQ, Bikowski JB, Baum E, et al. A closer look at truncal acne vulgaris: Prevalence, severity, and clinical significance. J Drugs Dermatol. 2007;6:597-600. 9. Data on file. Galderma Laboratories, L.P. 10. Parente ME, Gambaro A, Solana G. Study of sensory properties of emollients used in cosmetics and their correlation with physicochemical properties. J Cosmet Sci. 2005;56(3):175-182. 11. Personal Care Products Council. Nikitakis J, Lange B, eds. International Cosmetic Ingredient Dictionary and Handbook. Vol. 1. 16th ed. Washington, DC: 2016. (299,65). 12. Sehti A, Kaur T, Malhotra SK, Gambhir ML. Moisturizers: The slippery road. Indian J Dermatol. 2016;61(3):279-287.

IMPORTANT SAFETY INFORMATION

Indication: AKLIEF® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream were application site irritation, application site pruritus (itching), and sunburn. Warnings/Precautions: Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Use a moisturizer from the initiation of treatment, and, if appropriate, depending upon the severity of these adverse reactions, reduce the frequency of application of AKLIEF Cream, suspend or discontinue use. Avoid application of AKLIEF Cream to cuts, abrasions or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with AKLIEF Cream. Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Your use of this website is subject to our Updated Privacy Policy. Click here to read more.
up